RecruitingNCT06335277
Total Body Irradiation Treatments for Patients Treated at European Institute of Oncology
Sponsor
European Institute of Oncology
Enrollment
50 participants
Start Date
Feb 22, 2018
Study Type
OBSERVATIONAL
Conditions
Summary
Patients eligible undergoing total body irradiation as candidates for bone marrow or peripheral stem cell transplant.
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This registry study is collecting data on patients who receive total body irradiation (TBI) — a type of full-body radiation therapy — as preparation for a bone marrow or stem cell transplant. The goal is to better understand outcomes, side effects, and treatment patterns over time.
**You may be eligible if...**
- You are a patient who is receiving or has received total body irradiation as part of preparation for a bone marrow or stem cell transplant
- You have provided signed informed consent
**You may NOT be eligible if...**
- You are not undergoing total body irradiation
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06335277
Related Trials
Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy
NCT052379863 locations
Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)
NCT055363491 location
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
NCT06578247288 locations
Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas
NCT032585671 location
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma
NCT047398131 location